Sudeep Pharma's Q3 FY 2025-26 Quarterly Results
- 07 Feb 2026
Result Summary
- Sudeep Pharma Ltd reported a 3.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were up by 3.6% QoQ and - - YoY.
- The net profit increased 2.0% QoQ and - - YoY.
- The earnings per share (EPS) of Sudeep Pharma Ltd stood at 4.29 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 179.17 | 172.83 | 0.00 | 3.7% | - |
Total Expenses | 117.39 | 113.29 | 0.00 | 3.6% | - |
Profit Before Tax | 61.78 | 59.53 | - | 3.8% | NaN% |
Tax | 14.08 | 12.76 | 0.00 | 10.3% | - |
Profit After Tax | 47.70 | 46.78 | 0.00 | 2.0% | - |
Earnings Per Share | 4.29 | 4.20 | 0.00 | 2.1% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sudeep Pharma Ltd is a company operating in the pharmaceutical industry, primarily engaged in the production and distribution of pharmaceutical products. As of the last update in October 2023, specific details about the company's main products or any recent major developments are not directly provided in the data. Typically, companies in this industry focus on the development, manufacturing, and marketing of drugs and other health-related products. However, without additional information, further specifics regarding Sudeep Pharma Ltd's operations and strategic initiatives remain unavailable.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Sudeep Pharma Ltd reported a total income of ₹179.17 crores, which reflects a quarter-over-quarter (QoQ) increase of 3.7% from ₹172.83 crores in the second quarter of the same fiscal year (Q2FY26). The year-over-year (YoY) comparison with the third quarter of the previous fiscal year (Q3FY25) is not available due to the absence of data from that period. The revenue figures indicate a positive growth trajectory in the company's income over the recent quarter.
Profitability
Sudeep Pharma Ltd's profitability metrics for Q3FY26 demonstrate a positive performance. The company achieved a profit before tax of ₹61.78 crores, up 3.8% from ₹59.53 crores in Q2FY26. The tax expenses increased by 10.3% to ₹14.08 crores, leading to a profit after tax of ₹47.70 crores, which is a 2.0% increase from the previous quarter's ₹46.78 crores. Earnings per share in Q3FY26 were ₹4.29, compared to ₹4.20 in Q2FY26, marking a 2.1% rise. No year-over-year data is available for these profitability metrics due to missing figures from Q3FY25.
Operating Metrics
The operating metrics for Sudeep Pharma Ltd indicate an increase in both total income and total expenses, with a QoQ rise of 3.7% and 3.6%, respectively, in Q3FY26. The company's financial figures reflect a consistent pattern of growth in operating income and expenses, although specific operating ratios, such as P/E ratio, debt-to-equity ratio, or current ratio, are not available in the provided data. The absence of year-over-year comparisons limits a comprehensive analysis of longer-term trends within the operating metrics.